On September 15, Tempus AI rose 5.14% in regular trading, trading around $65.36 per share, with turnover of approximately $42.85 million. The rally was driven by a cluster of recent positive developments reinforcing the company's leadership in AI-powered healthcare.

On September 11, Tempus AI announced plans to build the world's largest multimodal whole-genome dataset, initially comprising 100,000 whole genome sequences paired with longitudinal clinical data, with a long-term goal of expanding to 1 million genomes. The dataset will be integrated into its existing de-identified multimodal platform, enabling researchers to access genomic information alongside clinical histories, imaging, pathology, and patient outcomes. General availability is planned for mid-2027.

Additionally, on September 10, the company secured up to $9.5 million from the Advanced Research Projects Agency for Health to develop an autonomous clinical AI agent for heart-failure care, building on its existing FDA-cleared ECG-AI products. These developments follow the FDA's 510(k) clearance on August 24 for its AI-enabled pulmonary hypertension detection software. Meanwhile, Piper Sandler upgraded Tempus AI to overweight with a $76 price target, and Cantor Fitzgerald initiated coverage at overweight with an $80 target.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)